Emerging Science Series - April 25, 2012
Protecting Cerebrovascular Function - From Translational Science to Clinical Trials
Wednesday, April 25, 2012, Noon–1:05 p.m.
|Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial
Presenter: Jonathan P. Piccini, Duke Clinical Research Institute, Duke University Medical Center, Durham, N.C.
|Cerebrovascular Autoregulation Impairment is Associated with Elevations in Plasma Glial Fibrillary Acidic Protein During Congenital Heart Surgery
Presenter: Ronald B. Easley, Baylor College of Medicine, Houston, Texas